ArticleTransplantation and cellular therapy2026
Outcomes of Terminal Complement Blockade in Adults with High-Risk Transplant-Associated Thrombotic Microangiopathy: A Comparative Analysis.
Article in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TA-TMA and GVHD are distinct consequences of endothelial injury: a MIDAS consortium study.Blood advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
High-risk transplant-associated thrombotic microangiopathy (hrTA-TMA), marked by organ dysfunction with concurrent graft-versus-host disease (GVHD) or infection, leads to poor outcomes after allogeneic hematopoietic cell transplantation (alloHCT). Terminal complement blockade is effective in pediatric patients with hrTA-TMA, but its efficacy and safety in adult patients are unclear. To compare clinical and safety outcomes of adults with hrTA-TMA treated with terminal complement blockade versus conventional therapy. We retrospectively included adults who underwent alloHCT between 2012 and 2023 and developed hrTA-TMA, defined per Harmonization criteria. Time-to-event analyses began at TA-TMA diagnosis, with outcomes including death, relapse, and non-relapse mortality (NRM). The impact of eculizumab on these outcomes was assessed using time-dependent Cox regression models. Models were adjusted for baseline TA-TMA biomarkers (lactate dehydrogenase, platelet count, and creatinine) to account for disease severity at diagnosis. A total of 47 hrTA-TMA patients were included: 16 received eculizumab, and 31 received conventional therapy. With a median follow-up of 7.3 yr, the 1-yr overall survival (OS) for entire cohort was 61% (95% CI, 47% to 75%), and 45% at 2 yr (95% CI, 31% to 60%). NRM was 32% at 1 yr (95% CI, 19% to 46%) and 44% at 2 yr (95% CI, 29% to 58%). Clinical response occurred in 56% with eculizumab and 71% with conventional therapy. The eculizumab cohort had worse OS (P < .001), with a higher hazard ratio (HR) for death at 6 mo (HR 5.8), 1 yr (HR 4.4), and 2 yr (HR 2.5). This was driven by increased NRM (P < .001) at 6 mo and 1 yr (HR 5.3) and 2 yr (HR 3.7), with no significant difference in relapse. Survival outcomes remained consistent after adjusting for hrTA-TMA biomarkers. Deaths were mainly due to infections in the eculizumab group versus GVHD in conventional therapy. In adults with hrTA-TMA after alloHCT, terminal complement blockade did not improve outcomes and was associated with higher NRM. Prospective studies are needed to better define its therapeutic role and optimal application in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.